The WHO global programme for vaccines and immunization vaccine trial registry

Bulletin of the World Health Organization

Volumn 75, Issue 4, 1997, Pages 295-305

  Robertson, S E ^a   Vall Mayans, M ^a,b   Horsfall, S ^a   Wright, P F ^c   Clemens, J ^d   Ivanoff, B ^a   Lambert, P H ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Ctr Epidemiol Studs AIDS C   (Spain)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

IMMUNIZATION PROGRAMME; VACCINE REGISTRY; WORLD HEALTH ORGANISATION;

ARTICLE; DEVELOPING COUNTRY; EVALUATION AND FOLLOW UP; HEALTH PROGRAM; HUMAN; IMMUNIZATION; NONHUMAN; VACCINATION; WORLD HEALTH ORGANIZATION;

DELIVERY OF HEALTH CARE; ECONOMIC FACTORS; HEALTH; HEALTH SERVICES; IMMUNIZATION; INTERNATIONAL AGENCIES; ORGANIZATIONS; PRIMARY HEALTH CARE; RESEARCH ACTIVITIES; RESEARCH AND DEVELOPMENT; RESEARCH METHODOLOGY; TECHNOLOGY; UN; VACCINATION; VACCINES; WHO;

ADOLESCENT; ADULT; BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; CHOLERA VACCINES; CLINICAL TRIALS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; ESCHERICHIA COLI; EUROPE, EASTERN; HUMANS; IMMUNIZATION; INFANT; INFANT, NEWBORN; MEASLES VACCINE; MIDDLE AGED; POLIOVIRUS VACCINE, INACTIVATED; REGISTRIES; STREPTOCOCCUS PNEUMONIAE; VACCINES; WORLD HEALTH ORGANIZATION;

EID: 0030819888     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. WHO/UNDP Programme for Vaccine Development. Report of the tenth session of the Scientific Advisory Group of Experts (SAGE). Geneva, World Health Organization, unpublished document MIM.PVD/93.8, 1993 (available upon request from Global Programme on Vaccines and Immunization, World Health Organization, 1211 Geneva 27, Switzerland).
2. Robertson SE. Research and development within the Expanded Programme on Immunization: the first five years. Geneva, World Health Organization, unpublished document WHO/EPI/GEN/93.10, 1993 (available upon request from Global Programme for Vaccines and Immunization, World Health Organization, 1211 Geneva 27, Switzerland).
3. Easterbrook PJ. Directory of registries of clinical trials. Statistics in medicine, 1992, 11: 345-423.
4. Moxon ER et al. A common European network for clinical trials. In: Bjovatn B, ed. European Commission COST/STD Initiative on European Vaccine Research: reports of the Expert Panels. Vaccine, 1996, 14: 624-643.
5. Fahey T et al. The type and quality of randomized controlled trials (RCTs) published in UK public health journals. Journal of public health medicine, 1995, 17: 469-474.
6. Milne R, Thorogood M. Hand searching the Journal of epidemiology and community health as part of the Cochrane Collaboration. Journal of epidemiology and community health, 1996, 50: 178-181.
7. Jefferson T, Jefferson V. The quest for trials on the efficacy of human vaccines: result of the handsearch of Vaccine. Vaccine, 1996, 14: 461-464.
8. WHO/GPV Vaccine Trial Registry Directory. Geneva, World Health Organization, unpublished document WHO/VRD/GEN/96.01, 1996 (available upon request from Global Programme for Vaccines and Immunization, World Health Organization, 1211 Geneva 27, Switzerland).
9. Dean AG et al. Epi Info, version 6: a word processing, database, and statistics program for epidemiology on microcomputers. Centers for Disease Control and Prevention, Atlanta, GA, USA, 1994.
10. The sex and age distribution of the world populations: the 1994 revision. United Nations, New York, 1994.
11. International list of availability of vaccines and sera. Geneva, World Health Organization, unpublished document WHO/VSQ/95.02/suppl.1, 1996 (available upon request from Global Programme for Vaccines and Immunization, World Health Organization, 1211 Geneva, 27, Switzerland).
12. Begg N, Miller E. Role of epidemiology in vaccine policy. Vaccine, 1990, 8: 180-189.
13. Hayes RB et al. More informative abstracts revisited. Annals of internal medicine, 1990, 113: 69-76.
14. WHO Collaborative Study Group on Oral Poliovirus Vaccine. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. Journal of infectious diseases, 1995, 171: 1097-1106.
15. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in the Gambia, Oman, and Thailand. Bulletin of the World Health Organization, 1996, 74: 253-268.
16. Lambert PH. Research priorities for vaccines to be used at a global level. Behring Institute Mitteilungen, 1994, 95: 1-6.
17. Wright PF. Approaches to prevent acute bacterial meningitis in developing countries. Bulletin of the World Health Organization, 1989, 67: 479-486.
18. Glass Rl, Gentsch JR, Ivanoff B. New lessons for rotavirus vaccines. Science, 1996, 272: 46-47.
19. Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. Bulletin of the World Health Organization, 1994, 72: 957-971.
20. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Reviews of infectious diseases, 1991, 13: 926-939.
21. Immunization policy. Geneva, World Health Organization, unpublished document WHO/EPI/GEN/95.03 rev. 1, 1996 (available upon request from Global Programme for Vaccines and Immunization, World Health Organization, 1211 Geneva 27, Switzerland).
22. Halsey N, Galazka A. The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age. Bulletin of the World Health Organization, 1985, 63: 1151-1169.
23. Hall AJ, Aaby P. Tropical trials and tribulations. International journal of epidemiology, 1990, 19: 777-781.
24. Clemens J et al. Evaluating new vaccines for developing countries: efficacy or effectiveness? Journal of the American Medical Association, 1996, 275: 390-397.
25. Cutts FT et al. Measles control in Kinshasa, Zaire improved with high coverage and use of medium titre Edmonston-Zagreb vaccine at age 6 months. International journal of epidemiology, 1994, 23: 624-631.
26. BCG immunization and paediatric HIV infection. Weekly epidemiological record, 1992, 67(18): 129-132.
27. Lepage P et al. Safety and immunogenicity of highdose Edmonston-Zagreb measles vaccine in children with HIV-1 infection: a cohort study in Kigali, Rwanda. American journal of diseases of children, 1992, 146: 550-555.
28. Moriniere B et al. Serologic responses to two Edmonston-Zagreb measles vaccines in 6-month-old infants, and to Schwarz measles vaccine in 9-month-old infants. In: Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, USA, 11-14 October 1992. Washington, DC, American Society for Microbiology, 1992: 180 (Abstract No. 416).
29. Moriniere BJ et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet, 1993, 341: 1545-1550.
30. Concha A et al. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia. Bulletin of the Pan American Health Organization, 1995, 29: 312-321.
31. Ahren C et al. Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic Escherichia coli vaccine. Vaccine, 1993, 11: 929-934.
32. Mulholland K et al. Randomised trial of Haemophilus influenzae type b-tetanus protein conjugate vaccine for prevention of pneumonia and meningitis in Gambian infants. Lancet, 1997, 349: 1191-1197.
33. Aaby P et al. Sex-specific differences in mortality after high-titre measles immunization in rural Senegal. Bulletin of the World Health Organization, 1994, 72: 761-770.
34. Auwaerter PG et al. Changes within T cell receptor V-beta subsets in infants following measles vaccination. Clinical immunology and immunopathology, 1996, 79: 163-170.
35. Bolotovski VM et al. Immunization of 6 and 9 month old infants with AIK-C, Edmonston-Zagreb, Leningrad-16 and Schwarz strains of measles vaccine. International journal of epidemiology, 1994, 23: 1069-1077.
36. Perkins BA et al. Immunogenicity of two outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. In: Proceedings of the Ninth International Pathogenic Neisseria Conference, Winchester, England, 26-30 September 1994.
37. Mas Lago P et al. Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bulletin of the World Health Organization, 1994, 72: 221-225.
38. Kok PW et al. Serological and virological assessment of oral and inactivated poliovirus vaccines in a rural population in Kenya. Bulletin of the World Health Organization, 1992, 70: 93-103.
39. Cohen-Abbo A et al. Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval. Pediatric infectious disease journal, 1995, 14: 100-106.